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Abstract. RTS,S/AS02 is a recombinant protein malaria vaccine that contains a large portion of the C-terminal of the
circumsporozoite protein (CSP) sequence of the NF54 isolate of Plasmodium falciparum fused to the hepatitis B virus
surface antigen. It has been shown to induce significant protection to challenge infection with a homologous parasite
strain in American volunteers. In a recently completed trial in semi-immune Gambian adults, vaccine efficacy against
natural infection was 34% (95% confidence interval  8–53%, P  0.014) during the malaria season following vacci-
nation. Breakthrough P. falciparum parasites sampled from vaccinated subjects and from controls were genotyped at two
polymorphic regions of the csp gene encoding T cell epitopes (csp-th2r and csp-th3r) to determine if the vaccine
conferred a strain-specific effect. The overall distribution of csp allelic variants was similar in infections occurring in
vaccine and control groups. Also, the mean number of genotypes per infection in the RTS,S/AS02 group was not reduced
compared with the controls.
INTRODUCTION
Several prototype Plasmodium falciparum vaccines have
undergone preliminary testing in naturally exposed human
populations, including circumsporozoite protein (CSP) vac-
cines against the pre-erythrocytic stage of the infection.1 Tri-
als of CSP vaccines have generally not shown good levels of
protection.2–4 However, encouraging results have been ob-
tained with a recombinant protein vaccine known as RTS,S/
AS02. This comprises most of the P. falciparum CSP se-
quence fused to hepatitis B virus surface antigen (HBsAg)
co-expressed as a fusion protein in yeast and formulated with
the adjuvant AS02.5 An initial trial in naive individuals
showed that RTS,S/AS02 conferred a high degree of protec-
tion against experimental P. falciparum sporozoite challenge
with parasites of the NF54 strain (3D7 clone) used to produce
the vaccine.5,6 Subsequent trials in naive individuals have
given similar degrees of protection.6–8 Evaluation of the effi-
cacy of RTS,S/AS02 against natural parasite challenge has
recently been undertaken in phase IIb trials in Gambian semi-
immune adults with rabies vaccine as the comparator.9 Over-
all, vaccine efficacy against infection during the malaria trans-
mission season following vaccination was 34% (95% confi-
dence interval [CI]  8–53%, P  0.014).9 Vaccine efficacy
was 71% (95% CI 46–85%) during the first nine weeks of
surveillance, but subsequently decreased to 0% (95% CI 
−52–34%) in the last six weeks.
To evaluate whether RTS,S/AS02 has a protective effect
only against parasites with a csp sequence similar to that of
NF54, parasites from breakthrough infections in control and
vaccine groups have been characterized at two highly poly-
morphic epitope sequences encoded within the csp gene, csp-
th2r and csp-th3r. In addition, we investigated whether vacci-
nation with RTS,S/AS02 led to a reduction in the mean num-
ber of P. falciparum genotypes per infection, as has been
described previously in trials with the SPf66 malaria vaccine
conducted in Tanzania and in The Gambia.10,11
MATERIALS AND METHODS
Study area, population, and design. The aim of the vaccine
trial was to evaluate the efficacy, safety, and immunogenicity
of RTS,S/AS02; the primary endpoint of efficacy was
first infection with P. falciparum. Details of the study area
and study design have been previously reported.12 Briefly,
adult male volunteers 18–45 years of age were recruited from
six villages in Basse in the Upper River Division of The
Gambia in 1998. Volunteers were given either three doses
of RTS,S/AS02 or rabies vaccine over a five-month peri-
od (February to August) before the malaria transmission
season (August to December). Pyrimethamine/sulfadoxine
(Fansidar; F. Hoffmann LaRoche, Basel, Switzerland) was
given two weeks before the third dose of vaccine to clear
blood stage infections. Starting two weeks after administra-
tion of the third dose of vaccine, volunteers were visited daily
by field workers who were posted to each of the six villages
for 15 weeks during the transmission season. Each week and
whenever a volunteer had symptoms compatible with ma-
laria, two thick blood films were made and three drops of
blood were spotted onto glass fiber membranes for parasite
genotyping. Only the first parasite-positive samples for each
subject were used in genotyping for allelic specificity of
RTS,S/AS02 at the csp-th2r and csp-th3r loci and for mea-
surement of the multiplicity of infection (MOI) at three un-
related loci.
Written informed consent was obtained from adult males
participating in the trial. The study was approved by the Joint
Gambia Government/Medical Research Council Ethics Com-
mittee, an Independent Data Safety Monitoring Committee,
and collaborating partners’ Institutional Review Boards. The
trial, which was conducted according to International Confer-
ence of Harmonisation (ICH) Good Clinical Practice guide-
lines, was monitored by the World Health Organization and
GlaxoSmithKline Biologicals.
Genotyping of csp polymorphic epitope sequences. Extrac-
tion of DNA and amplification by a polymerase chain reac-
tion (PCR) of a 319-base pair fragment of the csp gene were
performed as described previously.12 Samples of DNA were
amplified routinely in a single round PCR. However, samples
with low parasitemia were amplified in a second round PCR
using fresh primers, TaqDNA polymerase (BIOTAQ;™ Bio-
line, London, United Kingdom), and 1 l of PCR csp gene
product from the first PCR. PCR products were subsequently
tested by sequence-specific oligonucleotide probing, a tech-
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nique that was designed specifically for these investiga-
tions. The overall allele frequencies at both regions of the
csp sequence (th2r and th3r) were determined by counting
each allelic type detected in an isolate and dividing it by the
total number of alleles detected in the samples analyzed.
When more than one allele was present in an isolate, it was
necessary to score the results based on the relative intensity
of hybridization of the probes to each allele. In this way,
it was possible to determine the major allele, i.e., the allele
that gave the strongest hybridization signal (minor alleles
hybridized weakly but specifically to their respective probe).
Allele frequencies at csp-th2r and csp-th3r loci at the trial
site had been characterized in 1997 before the start of the
study.12
Genotyping of other markers to assess multiplicity of in-
fection. The same set of DNA samples was analyzed for
diversity at other genetic markers that contain polymor-
phic repeat sequences. The markers tested were within the
merozoite surface protein 1 (msp1), msp2, and glutamate-
rich protein (glurp) genes. An allele-specific, nested PCR
was used for the discrimination of msp1 block 2 and msp2
allelic families, and the allelic variants present within the
RII repeat region of glurp were detected by semi-nested
PCR.13 PCR products were resolved by electrophoresis
through Metaphore™ (FMC BioProducts, Rockland, ME)
agarose gels in 0.5× TBE buffer, stained with ethidium
bromide, and visualized by ultraviolet transillumination.
Bands corresponding to parasite allelic forms were distin-
guished by their size and counted and the number of geno-
types for msp1, msp2, and glurp loci determined for each
isolate. In addition, the overall MOI for each isolate was then
determined as the highest number of alleles observed at any
of the loci.
Statistical analyses. To test if RTS,S/AS02 vaccine efficacy
was allele-specific, we compared the frequency of the csp-
th2r*03 and csp-th3r*03 alleles (vaccine type) in breakthrough
infections in the vaccine and control groups using the chi-
square test. The Wilcoxon test14 was used for two-group com-
parisons and the Cuzick15 non-parametric linear trend test
was used when the groups were ordered (parasite density and
time). Poisson regression was used to produce estimates of
the vaccine effect on MOI adjusted for the effect of time,
village, and parasite density. The MOI values are presented as
means with SD values in Table 1.
RESULTS
Of 306 volunteers who were enrolled in the trial, 250 re-
ceived all three doses of vaccine (131 RTS,S/AS02 and 119
controls) and were followed-up for 15 weeks. One hundred
sixty-one volunteers had at least one episode of asexual par-
asitemia and DNA from 157 (98%) of these individuals was
successfully amplified by PCR and characterized at several
loci (77 from subjects in the RTS,S/AS02 group and 80 from
those in the controls). Forty-nine samples had low parasit-
emias (< 10 parasites/L), and for some of these it was nec-
essary to perform two rounds of PCR amplification before
genotyping at the csp-th2r and csp-th3r loci could be per-
formed. Age distribution, pre-vaccination anti-CSP and anti-
HBsAg antibody concentrations were similar in the two vac-
cine groups at enrolment and at the start of surveillance.
Genotyping at the csp-th2r and csp-th3r loci. The overall
allele frequencies were similar to those described previously
for a population sample in the trial site before vaccination.12
The primary analysis concentrated on the effects of vaccina-
tion with RTS,S/AS02 on the frequency of the NF54-like al-
lele in breakthrough infections when present either alone or
with other alleles. Fifteen alleles were detected at csp-th2r
locus (Figure 1a). No new types were detected. At the csp-
th3r locus, 10 alleles were detected (Figure 1b), and a small
number of new alleles were detected with low frequencies in
both groups (< 5%), but these were not characterized further.
The csp-th2r*03 allele (vaccine type for th2r sequence) was
present in nine of 77 infections in subjects in the RTS,S/AS02
group (12%) and in 13 of 80 infections in subjects in the
control group (16%) (P = 0.5), whereas csp-th3r*03 (vaccine
type for th3r sequence) was present in 27 of 77 infections in
subjects in the RTS,S/AS02 group (35%) and in 28 of 80
infections in the control group (35%) (P  0.9) (Figure 1).
These proportions are higher than the allele frequencies be-
cause some infections contained more than one parasite ge-
notype.
Analysis of MOI. One hundred fifty-seven DNA samples
were genotyped at the polymorphic loci msp1, msp2, and
glurp (all samples were successfully amplified at the three
loci). A high degree of genetic diversity was observed. Overall
MOI was significantly higher in the RTS,S/AS02 group than
in the controls, 4.90 and 4.23, respectively (P 0.05) (Table 1).
The ratio of control to RTS,S/AS02, which was estimated using
TABLE 1
Multiplicity of infections (MOI) at msp1, msp2, and glurp loci*
MOI
msp1 msp2 glurp Overall
Vaccine group† RTS,S/AS02 (n 77) 3.86 (1.85) 4.25 (2.11) 2.61 (1.50) 4.90 (2.13)
Controls (n 80) 3.54 (1.86) 3.45 (2.01) 2.11 (1.44) 4.23 (1.94)
P 0.31 P 0.006 P 0.03 P 0.05
Time to first infection‡ 0–59 days (n 49) 3.20 (1.54) 3.31 (1.62) 2.33 (1.48) 4.04 (1.49)
60–76 days (n 54) 3.69 (1.83) 3.76 (2.01) 2.13 (1.54) 4.35 (2.03)
77–111 days (n 54) 4.15 (2.05) 4.41 (2.41) 2.61 (1.42) 5.22 (2.36)
P 0.03 P 0.03 P 0.31 P 0.01
Parasite density/l <10 (n 46) 3.43 (1.87) 3.13 (1.76) 1.91 (1.38) 4.02 (1.91)
10–99 (n 60) 3.88 (1.83) 4.12 (2.06) 2.55 (1.53) 4.78 (2.02)
100 (n 51) 3.71 (1.88) 4.16 (2.27) 2.53 (1.46) 4.76 (2.17)
P 0.48 P 0.02 P 0.05 P 0.06
* msp  merozoite surface protein; glurp  glutamate-rich protein. Standard deviations for the MOI are in parentheses.
† 161 subjects who received 3 doses of vaccine developed parasitemia; 157 of 161 primary infections were genotyped.
‡ Time to infection and parasite density were grouped to give three groups with approximately equal numbers of infections in each group. P values were obtained using the non-parametric
trend test. Median time to infection was 82 days in the RTS,S/AS02 group and 73 days in the rabies group.
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Poisson regression and adjusting for effects of time period and
village by including these variables as factors in the model, was
0.96 (95% CI  0.81–1.13) for msp1, 0.84 (95% CI 0.71–0.99)
for msp2, 0.80 (95% CI  0.65–0.99) for glurp, and 0.88 (95%
CI  0.76–1.03) overall. The MOI increased during the trans-
mission season and was higher at the end of the season than at
the beginning (Table 1); however, there was no interaction be-
tween the effect of the vaccine group and the time to infection.
The MOI varied significantly be tween villages in the study area
and correlated positively with parasite density. No association
was seen between MOI and age.
DISCUSSION
This study demonstrates that RTS,S/AS02 protected Gam-
bian semi-immune adults against P. falciparum infections in a
FIGURE 1. Frequency distribution of the Plasmodium falciparum circumsporozoite surface protein (CSP) csp-th2r and csp-th3r alleles in the
RTS,S/AS02 vaccine (n 77) and control (n  80) groups. a, At the csp-th2r epitope, 196 alleles were detected in the RTS,S/AS02 group and
216 were detected in the control group. b, At the csp-th3r epitope, 197 alleles were detected in the RTS,S/AS02 group and 177 were detected in
the control group. Allele *03 at both csp-th2*03 and csp-th3r*03 corresponds to the vaccine type (NF54) and is indicated with an asterisk.
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non-allele-specific manner. Genotyping of breakthrough
parasites at the csp-th2r and csp-th3r epitopes showed that
allelic frequency of the vaccine-type allele sequences were
similar in both vaccine and control groups, although the vac-
cine had a marked effect on the incidence of infection. Fre-
quencies of all other csp allelic types were similar in the two
groups.
If RTS,S/AS02 had an allele-specific effect, a reduction in
the prevalence of the csp-th2r*03 and csp-th3r-03 alleles
should have been observed. Given the prevalence of the csp-
th3*03 allele (35%) and the sample size in each group, the
study had 99% power to detect a two-fold allele-specific ef-
fect of RTS,S/AS02. Since the prevalence of the vaccine type
at th2r (csp-thr2*03) was 16%, the study had 60% power to
detect a two-fold effect at that locus. Thus, the statistical
power was very high for th3r and reasonably high for th2r, so
the lack of an allele-specific effect is well supported.
Studies of immune responses elicited by vaccination with
RTS,S/AS02 suggest that protection may be mediated, at least
in part, by antibodies against the NANP(n) repeat region of
CSP, a conserved region among all P. falciparum parasite
strains.16 In the RTS,S/AS02 group, anti-CSP antibody levels
to the NANP(n) repeat region were 20 times higher after the
third dose than those in the control group and these levels
correlated with efficacy among the vaccinees.9
The vaccine also induced strong T cell responses as deter-
mined by proliferation and cultured ELISPOT (Millipore,
Watford, England) to many peptides in the th2r and th3r
epitopes of csp, although, given the small numbers studied for
these responses it has yet to be examined whether these re-
sponses were associated with protection.9 Our decision to
analyze csp-th2r and csp-th3r epitopes for correlation with
protection was based partly on the absence of real T-cell pro-
tective epitopes, and partly on existing suggestive data8,17,18
that these two epitopes might be protective.
The T cell responses to peptides within the conserved CST3
region apparently correlated with protection.9 This and the
conserved NANP(n) antibody epitope might explain why
there was no specific effect on the frequency of any allelic
type of csp in vaccinees compared with controls.
Having established that RTS,S/AS02 vaccine did not have
any effect on the distribution of alleles at the csp-th2r and
csp-th3r loci, the possibility that it reduced the genetic com-
plexity of infection (MOI) as assessed by typing of unrelated
polymorphic loci was investigated. This approach was
prompted by reports that children vaccinated with another
malaria vaccine (SPf66) in Tanzania and The Gambia had a
slightly lower number of genotypes compared with the con-
trols.10,11
Differences in multiplicity were found between villages,
suggesting local variations in the level of transmission, and
these correlated with parasite density. Although the vaccine
reduced the incidence of infection, it did not reduce the mul-
tiplicity per infection compared with the controls. A liver-
stage vaccine would be expected to induce a reduction or no
change in the number of genotypes depending on whether it
was strain-specific, but this was not observed in this study.
However, overall vaccine efficacy was still maintained at 34%
at the end of the follow up-period.9
The molecular characterization of parasites in break-
through cases following vaccination with RTS,S/AS02 has
added another dimension to the understanding of the molecu-
lar mechanisms involved in conferring protection against a
specific parasite strain. This study has clearly demonstrated
that the effect of RTS,S/AS02 vaccine is not allele-specific.
The non-allelic protective efficacy of RTS,S/AS02 vaccine
should encourage the testing of this vaccine in transmission
settings where the NF54 strain is not the predominant type.
Molecular typing should become an integral part of the evalu-
ation of future malaria vaccine trials in which vaccines that
might be anticipated to have a strain specific effect is used.
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